ZYNE - ジナ―バ・ファ―マシュ―ティカルズ (Zynerba Pharmaceuticals Inc.)

ZYNEのニュース

   Making The Case For Zynerba Pharmaceuticals (NASDAQ:ZYNE)  2020/09/17 23:10:11 Seeking Alpha
Zynerba's Pivotal Phase 3 CONNECT-FX study is the first placebo-controlled study to show statistical significance in children with Fragile X Syndrome (FXS) to date - a significant accomplishment.
   Zynerba's cannabidiol an Orphan drug for a rare chromosomal disorder (NASDAQ:ZYNE)  2020/09/17 17:49:52 Seeking Alpha
The FDA has granted Orphan drug status for Zynerba's (ZYNE +6.2%) cannabidiol as a treatment of 22q.11.2 deletion syndrome, according to a post to the agen
   Zynerba Pharmaceuticals : August, 2020 Corporate Presentation | MarketScreener  2020/08/10 12:19:02 MarketScreener
pivotal trial complete Developmental and epileptic encephalopathies - Phase 2 complete Autism spectrum… | August 10, 2020
   Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights  2020/08/10 10:45:00 GlobeNewswire
DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal…
   Cannabis Stock Gainers And Losers From August 4, 2020  2020/08/04 21:37:28 Benzinga
Gainers: MGC Pharmaceuticals (OTC: MGCLF ) shares closed up 72.5% at $0.04 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 20.97% at $0.08 Tilray (NASDAQ: TLRY ) shares closed up 17.09% at $8.70 InMed Pharmaceuticals (OTC: IMLFF ) shares closed up 13.81% at $4.78 EnWave (OTC: NWVCF ) shares closed up 12.9% at $0.80 CV Sciences (OTC: CVSI ) shares closed up 11.61% at $0.74 Halo Labs (OTC: AGEEF ) shares closed up 9.76% at $0.09 Alcanna (OTC: LQSIF ) shares closed up 8.99% at $3.03 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up … Full story available on Benzinga.com
   Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options  2020/05/28 12:42:00 Zacks Investment Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
   Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session  2020/05/26 10:52:00 GlobeNewswire
- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX…
   Cannabis Stock Gainers And Losers From May 18, 2020  2020/05/18 20:47:48 Benzinga Feeds
Gainers Aurora Cannabis (NYSE: ACB ) shares closed up 56.51% at $17.06 Emerald Health (OTC: EMHTF ) shares closed up 45.39% at $0.17 HEXO (NYSE: HEXO ) shares closed up 42.74% at $0.76 Green Organic Dutchman (OTC: TGODF ) shares closed up 38.75% at $0.28 Item 9 Labs (OTC: INLB ) shares closed up 26.87% at $0.85 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 21.95% at $4.89 MedMen Enterprises (OTC: … Full story available on Benzinga.com
   Cannabis Stock Gainers And Losers From March 23, 2020  2020/03/23 18:54:00 Benzinga
Gainers Cresco Labs (OTC: CRLBF) shares closed up 14.1% at $2.80 Zynerba Pharmaceuticals (NASDAQ: ZYNE) shares closed up 12.62% at …
   Medical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook 'Promising'  2020/03/10 16:40:05 Benzinga
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) shares were trading higher Tuesday after the cannabinoid devloper posted its financial report for the fourth quarter and full year 2019. The company reported zero revenue versus $86,000 in the fourth quarter of 2018. For the quarter, the company posted a net loss of $10.71 million, or 46 cents per share, higher than the net loss of $7.8 million and 44 cents per share in the same period of 2018. For the full year, Zynerba's net loss amounted to $32.94 million or $1.50 per share versus a loss of … Full story available on Benzinga.com
   Cannabis Stock Gainers And Losers From March 23, 2020  2020/03/23 18:54:00 Benzinga
Gainers Cresco Labs (OTC: CRLBF) shares closed up 14.1% at $2.80 Zynerba Pharmaceuticals (NASDAQ: ZYNE) shares closed up 12.62% at …
   Medical CBD Company Zynerba Rallies On Q4 Report, CEO Says 2020 Outlook 'Promising'  2020/03/10 16:40:05 Benzinga
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ) shares were trading higher Tuesday after the cannabinoid devloper posted its financial report for the fourth quarter and full year 2019. The company reported zero revenue versus $86,000 in the fourth quarter of 2018. For the quarter, the company posted a net loss of $10.71 million, or 46 cents per share, higher than the net loss of $7.8 million and 44 cents per share in the same period of 2018. For the full year, Zynerba's net loss amounted to $32.94 million or $1.50 per share versus a loss of … Full story available on Benzinga.com
   Cannabis Stock Gainers And Losers From Feb. 25, 2020  2020/02/25 21:47:02 Benzinga Feeds
Gainers ProPetro Holding (NYSE: PUMP ) shares increased by 9.65%, to close at $10.00 Benchmark Botanics (OTC: BHHKF ) shares rose 15.38%, closing at $0.30 MariMed (OTC: MRMD ) shares increased by 5.58%, closing at $0.32 Neptune Wellness Solns (NASDAQ: NEPT ) shares gained 7.81%, closing at $2.07 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares increased 7.13%, to close at $4.96 TerrAscend (OTC: TRSSF ) shares gained 5.15%, to close at $2.23 Halo Labs (OTC: Full story available on Benzinga.com
   Zynerba Pharma meets patient screening target for Zygel trial; shares up 3% premarket  2020/02/03 14:26:53 Seeking Alpha
Zynerba Pharmaceuticals (NASDAQ:ZYNE) has successfully achieved patient screening target in its 14-week CONNECT-FX (Clinical study of Cannabidiol (CBD) in
   MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm  2019/12/20 21:01:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #ZYNE--MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynerba Pharmaceuticals, Inc.

calendar